Tags

Type your tag names separated by a space and hit enter

Biochemical and pathological evaluation of albendazole/thalidomide co-therapy against eosinophilic meningitis or meningoencephalitis induced by Angiostrongylus cantonensis.
J Antimicrob Chemother. 2007 Feb; 59(2):264-76.JA

Abstract

OBJECTIVES

To evaluate the curative effect of albendazole/thalidomide co-therapy on eosinophilic meningitis in BALB/c mice caused by Angiostrongylus cantonensis.

METHODS

Male mice were infected with 50 A. cantonensis larvae and treated with albendazole (5, 10 or 20 mg/kg per day) alone, thalidomide (25, 50 or 100 mg/kg per day) alone, or a combination of albendazole (10 mg/kg per day) and thalidomide (50 mg/kg per day) for 7 consecutive days on days 5, 10 and 15 post-inoculation (PI), respectively.

RESULTS

Indicators used to measure this effect included: (i) worm recovery; (ii) histopathological score of meningitis; (iii) eosinophil counts; (iv) level of pro-inflammatory cytokines, such as tumour necrosis factor-alpha, interleukin-1beta and interleukin-5; (v) activity of enzymes, such as tissue-type plasminogen activator, urokinase-type plasminogen activator and matrix metalloproteinase-9; and (vi) CSF/serum albumin ratio. The results showed that albendazole/thalidomide co-therapy significantly decreased (P < 0.05) these factors when treatment was initiated on days 5 or 10 PI compared with treatment initiated on day 15 PI.

CONCLUSIONS

The timing of medication use is important and is closely related to the anthelmintic efficacy of a drug. For a given dosage, earlier medication use is more effective. This novel approach to treating parasitic meningitis may suggest other new methods of treatment.

Authors+Show Affiliations

Department of Parasitology, Chung Shan Medical University, Taichung 402, Taiwan.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17298991

Citation

Chen, Ke-Min, and Shih-Chan Lai. "Biochemical and Pathological Evaluation of Albendazole/thalidomide Co-therapy Against Eosinophilic Meningitis or Meningoencephalitis Induced By Angiostrongylus Cantonensis." The Journal of Antimicrobial Chemotherapy, vol. 59, no. 2, 2007, pp. 264-76.
Chen KM, Lai SC. Biochemical and pathological evaluation of albendazole/thalidomide co-therapy against eosinophilic meningitis or meningoencephalitis induced by Angiostrongylus cantonensis. J Antimicrob Chemother. 2007;59(2):264-76.
Chen, K. M., & Lai, S. C. (2007). Biochemical and pathological evaluation of albendazole/thalidomide co-therapy against eosinophilic meningitis or meningoencephalitis induced by Angiostrongylus cantonensis. The Journal of Antimicrobial Chemotherapy, 59(2), 264-76.
Chen KM, Lai SC. Biochemical and Pathological Evaluation of Albendazole/thalidomide Co-therapy Against Eosinophilic Meningitis or Meningoencephalitis Induced By Angiostrongylus Cantonensis. J Antimicrob Chemother. 2007;59(2):264-76. PubMed PMID: 17298991.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biochemical and pathological evaluation of albendazole/thalidomide co-therapy against eosinophilic meningitis or meningoencephalitis induced by Angiostrongylus cantonensis. AU - Chen,Ke-Min, AU - Lai,Shih-Chan, PY - 2007/2/15/pubmed PY - 2007/3/23/medline PY - 2007/2/15/entrez SP - 264 EP - 76 JF - The Journal of antimicrobial chemotherapy JO - J Antimicrob Chemother VL - 59 IS - 2 N2 - OBJECTIVES: To evaluate the curative effect of albendazole/thalidomide co-therapy on eosinophilic meningitis in BALB/c mice caused by Angiostrongylus cantonensis. METHODS: Male mice were infected with 50 A. cantonensis larvae and treated with albendazole (5, 10 or 20 mg/kg per day) alone, thalidomide (25, 50 or 100 mg/kg per day) alone, or a combination of albendazole (10 mg/kg per day) and thalidomide (50 mg/kg per day) for 7 consecutive days on days 5, 10 and 15 post-inoculation (PI), respectively. RESULTS: Indicators used to measure this effect included: (i) worm recovery; (ii) histopathological score of meningitis; (iii) eosinophil counts; (iv) level of pro-inflammatory cytokines, such as tumour necrosis factor-alpha, interleukin-1beta and interleukin-5; (v) activity of enzymes, such as tissue-type plasminogen activator, urokinase-type plasminogen activator and matrix metalloproteinase-9; and (vi) CSF/serum albumin ratio. The results showed that albendazole/thalidomide co-therapy significantly decreased (P < 0.05) these factors when treatment was initiated on days 5 or 10 PI compared with treatment initiated on day 15 PI. CONCLUSIONS: The timing of medication use is important and is closely related to the anthelmintic efficacy of a drug. For a given dosage, earlier medication use is more effective. This novel approach to treating parasitic meningitis may suggest other new methods of treatment. SN - 0305-7453 UR - https://www.unboundmedicine.com/medline/citation/17298991/Biochemical_and_pathological_evaluation_of_albendazole/thalidomide_co_therapy_against_eosinophilic_meningitis_or_meningoencephalitis_induced_by_Angiostrongylus_cantonensis_ L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkl492 DB - PRIME DP - Unbound Medicine ER -